{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.72","value":"26.02"},{"groupId":"OG001","spread":"21.19","value":"26.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"description":"Minocycline tested for its ability to reduce the value of a patient's 3 month (± two days) area under the curve (AUC) for the mean of 5 symptoms: fatigue, pain, muscle weakness, numbness, and bone aches. The AUC is calculated using a trapezoidal approximation, derived by multiplying half of the base with the sum of the two heights. The two heights correspond to the two mean symptom scores computed at each of these assessments. The AUC is measured in units of mean MDASI score in days. The area for the subsequent trapezoid can be calculated in the same way. Given a baseline, weekly assessment schedule over a three month period and end of trial assessment, there will be a total of 14 trapezoids. The AUC is the sum of the area of the 14 trapezoids. Each of the trapezoid has a maximum value of 70 (0.5\\*7 days\\*(10+10)). Hence, the AUC will have a minimum score of 0 and a maximum score of 980. Higher AUC values indicate worse outcomes.","dispersionType":"Standard Deviation","groups":[{"description":"Minocycline 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"OG000","title":"Minocycline"},{"description":"Placebo 100 mg (capsule) two times a day to begin with start of maintenance therapy (3 months +/- 2 days)","id":"OG001","title":"Placebo"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Baseline to 3 months (three cycles with assessments made at beginning of each)","title":"Symptom Reduction","type":"PRIMARY","unitOfMeasure":"units on a scale*month"}